Alzamend Neuro Inc 2025年度报告

FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended April 30, 2026 Commission file number 001-40483 ALZAMEND NEURO, INC. (Exact name of registrant as specified in its charter) Delaware81-1822909(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number) Securities registered under Section 12(b) of the Act: Securities registered under Section 12(g) of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule405 of the Securities Act.YesNo Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of 1934during the preceding year (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filingrequirements for the past 90days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule12b-2 of the Exchange Act. LargeacceleratedfilerNon-accelerated filerEmerging growth company AcceleratedfilerSmallerreportingcompany If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm thatprepared or issued its audit report. If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in thefiling reflect the correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensationreceived by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).YesNo The aggregate market value of the common stock held by non-affiliates of the registrant, based on the closing price of the shares of common stock onOctober 31, 2025 (the last business day of the registrant’s most recently completed second fiscal quarter), as reported by The Nasdaq Stock Market LLCon such date was approximately $9.6 million. Shares of the registrant’s common stock held by each executive officer and director and by each otherperson who may be deemed to be an affiliate of the registrant have been excluded from this computation. This calculation does not reflect a determinationthat certain persons are affiliates of the registrant for any other purpose. There were 4,791,525 shares of common stock outstanding as of July 22, 2026. Documents incorporated by reference:None ALZAMEND NEURO, INC. FORM 10-K FOR THE FISCAL YEAR ENDED APRIL 30, 2026 INDEX Item 1.Business2Item 1A.Risk Factors22Item 1B.Unresolved Staff Comments43Item 1C.Cybersecurity43Item 2.Properties44Item 3.Legal Proceedings44Item 4.Mine Safety Disclosures44PART II Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities45Item 6.[Reserved]45Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations46Item 7A.Quantitative and Qualitative Disclosures About Market Risk53Item 8.Financial Statements and Supplementary Data53Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure53Item 9A.Controls and Procedures53Item 9B.Other Information54Item 9C.Disclosures Regarding Foreign Jurisdictions that Prevent Inspections54PART III NOTE ABOUT FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (the “Annual Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of1933, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance.We have attempted to identify forward-looking statements by termin